Global Bulbospinal Muscular Atrophy Drugs Market, By Drug Class (5α-Reductase Inhibitors (5-ARIs), Gonadotropin-releasing Hormone (GnRH) Agonists and Others), Drugs (Leuprorelin, Dutasteride and Others), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others) - Industry Trends and Forecast to 2030.
Bulbospinal Muscular Atrophy Drugs Market Analysis and Size
Bulbospinal muscular atrophy (Kennedy’s disease) is a disease under which bulblike structure forms in the lower part of the brain that contains nerve cells controlling muscles in the face, mouth and throat. The condition occurs due to loss of nerve cells in the brain stem and spinal cord, this result in stoppage of messages from brain to muscles for movement. The patients suffering with this disease have difficulty in speaking, standing, walking and controlling their head movements. In worse condition patients can have trouble swallowing and breathing. This disorder mainly affects men and does not occur in females, who are protected by their low levels of testosterone in the body, accounting for the sex-limited inheritance pattern of this disorder.
Data Bridge Market Research analyses that the bulbospinal muscular atrophy drugs market which was USD 690.60 million in 2022, would reach up to USD 1,793.48 million by 2030, and is expected to undergo a CAGR of 12.67% during the forecast period. “Hospitals” dominates the end-user segment of the bulbospinal muscular atrophy drugs market owing to presence of higher number of hospitalized patients. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Bulbospinal Muscular Atrophy Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (5α-Reductase Inhibitors (5-ARIs), Gonadotropin-releasing Hormone (GnRH) Agonists and Others), Drugs (Leuprorelin, Dutasteride and Others), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Boehringer Ingelheim International GmbH (Germany), Pfizer Inc. (U.S.), Ionis Pharmaceuticals, Inc. (U.S.), CYTOKINETICS, INC. (U.S.), Regeneron Pharmaceuticals, Inc. (U.S.), Salarius Pharmaceuticals, Inc. (U.S.), Leadiant Biosciences, Inc. (Italy), Abbott (U.S.), Novo Nordisk A/S (Denmark), Takeda Pharmaceutical Company Limited (Japan), AstraZeneca (U.K.), Catalyst Pharma (U.S.), PTC Therapeutics (U.S.) and Natera (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Bulbospinal muscular atrophy (BSMA), also known as Kennedy's disease, is a rare genetic disorder characterized by the progressive degeneration of motor neurons in the spinal cord and brainstem. It primarily affects males and is caused by a mutation in the androgen receptor gene. BSMA leads to muscle weakness, atrophy, and a range of symptoms such as difficulty in speaking, swallowing, and breathing, and muscle cramps and twitching. Symptoms typically appear in adulthood, and the condition worsens over time. While there is currently no cure for BSMA, various treatments and therapies aim to manage its symptoms and improve the quality of life for affected individuals. Some of the therapeutic approaches include androgen deprivation therapy, physical and occupational therapy among others.
Global Bulbospinal Muscular Atrophy Drugs Market Dynamics
Drivers
- Increasing Prevalence and Diagnosis Rate
Advances in medical knowledge and genetic testing technologies have resulted in more accurate and timely diagnoses of rare diseases such as BSMA. As awareness among healthcare professionals and the public grows, the number of diagnosed cases is expected to increase. The expanding pool of identified BSMA patients creates a larger market for pharmaceutical companies developing drugs for the condition.
- Advancements in Genetic Research
Ongoing genetic research has deepened our understanding of the molecular mechanisms underlying BSMA. This knowledge is essential for the development of targeted therapies that address the genetic mutations responsible for the disease. As genetic research continues to uncover the intricacies of BSMA, it provides opportunities for the development of more effective and specific drugs.
Opportunities
- Development of Targeted Therapies
As research into the underlying genetic mechanisms of BSMA advances, there is potential for the development of more targeted and effective therapies. This could lead to the introduction of novel drugs that specifically address the genetic mutations responsible for BSMA, providing patients with more tailored treatment options.
- Increased Patient Awareness and Diagnosis
As awareness about BSMA grows among healthcare professionals and the public, more patients may be accurately diagnosed. This increased diagnosis rate can lead to a larger patient pool seeking treatment, thus expanding the market for BSMA drugs.
- Orphan Drug Incentives
BSMA is considered a rare disease, making it eligible for orphan drug status in many regions. This designation can provide drug developers with financial incentives, tax benefits, and market exclusivity, encouraging investment in BSMA drug research and development.
Restraints/Challenges
- Clinical Trial Challenges
Conducting clinical trials for rare diseases can be challenging due to the limited number of eligible participants. Recruitment and retention of patients for trials may be difficult, potentially delaying drug development timelines.
- High Development Costs
Developing drugs for rare diseases can be cost-intensive, and the potential return on investment may be uncertain due to the limited market size. This financial risk can deter some pharmaceutical companies from pursuing BSMA drug development
This bulbospinal muscular atrophy drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bulbospinal muscular atrophy drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Bulbospinal Muscular Atrophy Drugs Market Scope
The bulbospinal muscular atrophy drugs market is segmented on the basis of drug class, drugs, route of administration, distribution channel and end-users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- 5α-Reductase Inhibitors (5-ARIs)
- Gonadotropin-releasing Hormone (GnRH) Agonists
- Others
Drugs
- Leuprorelin
- Dutasteride
- Others
Route of Administration
- Oral
- Parenteral
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Bulbospinal Muscular Atrophy Drugs Market Regional Analysis/Insights
The bulbospinal muscular atrophy drugs market is analysed and market size insights and trends are provided by drug class, drugs, route of administration, distribution channel and end-users as referenced above.
The countries covered in the bulbospinal muscular atrophy drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America leads the bulbospinal muscular atrophy drugs market due to the increase in the prevalence of bulbospinal muscular atrophy and the unhealthy lifestyle.
Asia-Pacific region is expected to expand at a significant growth rate in the forecast period because of the rise in the population and increase in the healthcare awareness and the high adoption of healthcare solutions.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Bulbospinal Muscular Atrophy Drugs Market Share Analysis
The bulbospinal muscular atrophy drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to bulbospinal muscular atrophy drugs market.
Some of the major players operating in the bulbospinal muscular atrophy drugs market are:
- Novartis AG (Switzerland)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Boehringer Ingelheim International GmbH (Germany)
- Pfizer Inc. (U.S.)
- Ionis Pharmaceuticals, Inc. (U.S.)
- CYTOKINETICS, INC. (U.S.)
- Regeneron Pharmaceuticals, Inc. (U.S.)
- Salarius Pharmaceuticals, Inc. (U.S.)
- Leadiant Biosciences, Inc. (Italy)
- Abbott (U.S.)
- Novo Nordisk A/S (Denmark)
- Takeda Pharmaceutical Company Limited (Japan)
- AstraZeneca (U.K.)
- Catalyst Pharma (U.S.)
- PTC Therapeutics (U.S.)
- Natera (U.S.)
SKU-